"10.1371_journal.pone.0061916","plos one","2013-04-16T00:00:00Z","Chrysiis Michaloglou; Waltraut Lehmann; Typhaine Martin; Clara Delaunay; Andreas Hueber; Louise Barys; Honglin Niu; Eric Billy; Markus Wartmann; Moriko Ito; Christopher J Wilson; Mary Ellen Digan; Andreas Bauer; Hans Voshol; Gerhard Christofori; William R Sellers; Francesco Hofmann; Tobias Schmelzle","Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland; Novartis Institutes for BioMedical Research, Developmental and Molecular Pathways, Cambridge, Massachusetts, United States of America; Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry, Cambridge, Massachusetts, United States of America; Novartis Institutes for BioMedical Research, Developmental and Molecular Pathways, Basel, Switzerland; Department of Biomedicine, Institute of Biochemistry and Genetics, University of Basel, Basel, Switzerland; Novartis Institutes for BioMedical Research, Disease Area Oncology, Cambridge, Massachusetts, United States of America","Conceived and designed the experiments: CM TS GH WRS FH HV. Performed the experiments: CM WL TM CD LB EB HV. Analyzed the data: CM WL TS MI HV. Contributed reagents/materials/analysis tools: AH MW HN MED CW GC AB. Wrote the paper: CM TS.","The authors have read the journals policy and have the following conflicts: CM, WL, TM, CD, AH, LB, HN, EB, MW, MI, CJW, MED, AB, HV, WRS, FH and TS are or were employees of Novartis Pharma AG. GC declares no conflict of interest. This study was carried out as part of a postdoctoral project within Novartis and in collaboration with the academic mentor GC. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","04","Chrysiis Michaloglou","CM",18,TRUE,6,7,5,2,TRUE,TRUE,FALSE,0,NA,FALSE
